Reovirus modulates autophagy during oncolysis of multiple myeloma

Autophagy. 2013 Mar;9(3):413-4. doi: 10.4161/auto.22867. Epub 2013 Jan 15.

Abstract

Multiple myeloma (MM) is a clonal plasma cell malignancy that accounts for 10-15% of newly diagnosed hematological cancers. Although significant advances have been made in the treatment of MM the disease still remains incurable. The oncolytic potential of reovirus has previously been demonstrated by others and us and is currently in phase III clinical trials for solid tumors. In addition a phase I clinical trial has recently been initiated for MM. Despite the clinical activity, the mechanism(s) of cell death caused by reovirus in MM is yet not yet well elucidated. A comprehensive understanding of reovirus-mediated histology-specific cell death mechanisms is imperative if this therapeutic is to become a standard of care for patients. Previously we have shown that reovirus-mediated cell death of breast and prostate cancer is orchestrated via apoptosis. The present study demonstrates for the first time that in addition to inducing apoptosis reovirus also upregulates autophagy during oncolysis of MM.

Keywords: apoptosis; autophagy; multiple myeloma; reovirus.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Apoptosis*
  • Autophagy*
  • Cell Line, Tumor
  • Clinical Trials as Topic
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Multiple Myeloma / metabolism
  • Multiple Myeloma / therapy*
  • Oncolytic Virotherapy / methods*
  • Reoviridae / physiology*

Substances

  • Antineoplastic Agents